Combine this with a large increase in funding, and you could start to see the rewards of leading a UK biotech company to success start to become enticing – the $354 million that David Hung ...

The United Kingdom aims to boost its life sciences profile as Aviva Capital Partners and Socius unveiled plans for a £1 ...

M42, the Abu Dhabi-based tech-enabled global health company specializing in artificial intelligence (AI), advanced technology ...

biotech stocks then file for approval from drug regulators such as the MHRA in the UK and FDA in the US. This process can take anywhere between 6 and 10 months and may require the company to ...

Between the beginning of the year and 28 April, biotech trusts’ share prices dropped by between 11 per cent and 20 per cent, despite a partial bounce back in the second half of April.

Stablepharma Ltd is a high-growth biotechnology company based in the UK and Spain, with the mission to reduce reliance on the pharmaceutical cold-chain. Stablepharma's vision is to save lives ...

Under the terms of the proposed deal, Medicus will acquire all of the outstanding shares of Antev in exchange for 2,666,600 shares of Medicus stock. Montco pharma firm targeting $20B industry ...